Biogen Shares Tick Higher After Phase 2 CELIA Data for Diranersen
Biogen Inc. shares rose modestly after the company disclosed Phase 2 CELIA study results for diranersen, an antisense oligonucleotide targeting tau. The data, presented at a major Alzheimer’s conference, showed efficacy across doses at 18 months with the 60 mg dose producing the largest slowing of cognitive decline on multiple endpoints and marked …